Hansen Gwenn Sells 4,111 Nurix Therapeutics Shares at $24.64 Each

Nurix Therapeutics' Chief Scientific Officer, Hansen Gwenn, sold 4,111 shares of the company at $24.64 each, totaling $101,141, according to data filed with the SEC.

Who is Hansen Gwenn and What is His Real Role at Nurix Therapeutics

Hansen Gwenn is the Chief Scientific Officer of Nurix Therapeutics, a biopharmaceutical company focused on developing treatments for serious diseases. In this role, Hansen Gwenn plays a key part in the company's scientific direction and has access to privileged information about the company's research and development projects. His responsibilities include overseeing the company's research and development activities and making strategic decisions regarding the company's scientific objectives.

As part of Nurix Therapeutics' leadership team, Hansen Gwenn has an in-depth understanding of the company's activities and prospects. He is responsible for implementing the company's scientific strategy and works closely with other members of the leadership team to achieve the company's goals. His expertise and experience in the biomedical sciences are crucial to the company's success.

Hansen Gwenn's role as Chief Scientific Officer also gives him access to confidential information about research results, clinical trials, and future developments of the company. This information is essential for making informed decisions regarding the company's strategy and investments in new projects. As a company insider, Hansen Gwenn is obligated to report his stock transactions to the SEC within two business days of the trade.

Transaction Details: 4,111 shares at $24.64 each

Hansen Gwenn's transaction involved the sale of 4,111 Nurix Therapeutics shares at a price of $24.64 per share. The total value of the transaction was $101,141. It is important to note that the per-share price and the total transaction value are two distinct figures. The per-share price represents the amount paid for each share, while the total transaction value represents the total amount paid for all shares sold.

The date of the transaction was August 5, 2026, and the transaction was reported to the SEC within two business days of the trade, in compliance with SEC rules. The transaction data is publicly accessible via the SEC's EDGAR system, which allows investors to track transactions by company insiders and board members.

Why Insiders Sell Their Shares - Possible Reasons

There are several reasons why insiders, such as Hansen Gwenn, may choose to sell their shares. One possible reason is portfolio diversification. Company executives and board members often have a significant portion of their wealth invested in their own company's stock. By selling some of their shares, they can diversify their portfolio and reduce their exposure to the company.

Another possible reason is tax planning. Insiders may sell their shares to realize capital gains and pay the corresponding taxes. This can be particularly important for executives and board members who acquired shares at a lower price and wish to realize capital gains before tax rates increase.

Insiders may also sell their shares for personal reasons, such as the need for liquidity to